Abstract
Simple SummaryCirculating tumor cells (CTCs) and CD31+ circulating tumor endothelial cells (CTECs) constitute a unique pair of cellular circulating tumor biomarkers and play a crucial role in cancer metastasis and disease progression. Precise detection of live and necrotic aneuploid CTCs and CTECs in therapeutic cancer patients, though clinically highly demanded, has yet to be achieved in the field. The aim of this study is to develop a comprehensive strategy to effectively distinguish and co-detect viable and dead non-hematological cancer cells harboring aneuploid chromosomes and expressing various tumor markers. The innovative strategy developed in the present study will assist in an efficient assessment of therapy effectiveness, rapid detection of emerging treatment resistance and bringing in new insights into the comprehension of cancer cells in circulation.Aneuploid circulating tumor cells (CTCs, CD31−) and circulating tumor endothelial cells (CTECs, CD31+) exhibit an active interplay in peripheral blood, and play an essential role in tumorigenesis, neoangiogenesis, disease progression, therapy-resistant minimal residual disease (MRD), cancer metastasis and relapse. Currently, most CTC detection techniques are restricted to the indistinguishable quantification of circulating rare cells, including both necrotic and viable cells in cancer patients. Clinically imperative demands to distinguish and detect live and/or dead non-hematological aneuploid cancer cells in peripheral blood, which will assist in the rapid evaluation of therapeutic effects, real-time monitoring of treatment resistance longitudinally developed along with therapy and the effective detection of post-therapeutic MRD, have not yet been achieved. The integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)-derived novel strategy was developed in this study, aiming to precisely identify and detect live and necrotic cancer cells (NC) enriched from carcinoma patients’ biofluids. The innovative SE-iFISH (NC) provides a meaningful and practical approach to co-detect various viable and necrotic aneuploid CTCs and CTECs. The detected circulating rare cells can be characterized and categorized into diverse subtypes based upon cell viability, morphology, multiple tumor markers’ expression, and the degree of aneuploidy relevant to both malignancy and therapeutic resistance. Each subtype of live or necrotic CTCs and CTECs possesses distinct utility in anti-cancer drug development, translational research, and clinical practice.
Highlights
Licensee MDPI, Basel, Switzerland.Circulating tumor cells (CTCs), a biomarker of liquid biopsy, play an essential role in risk stratification, molecular staging of disease progression, detection and characterization of minimal residual disease (MRD) in cancer patients [1,2,3]
The highly heterogeneous expression of EpCAM on non-small cell lung cancer (NSCLC) cells revealed in this study keeps in accordance with that previously reported by others and us [19,35]
Programmed necrosis of endothelial cells (ECs), or tumor endothelial cells (TECs) induced by cancer cells, was found to accelerate necroptotic TECs’ release of factors that promote extravasation [40], suggesting both viable CTCs and circulating tumor endothelial cells (CTEC) play a pivotal role in the metastasis cascade
Summary
Licensee MDPI, Basel, Switzerland.Circulating tumor cells (CTCs), a biomarker of liquid biopsy, play an essential role in risk stratification, molecular staging of disease progression, detection and characterization of minimal residual disease (MRD) in cancer patients [1,2,3]. Real-time liquid biopsy of tumor-derived cellular and molecular signatures in cancer patients’ peripheral blood provides strong evidence of an estimation of early treatment response during the management of cancers, when the resection of tumor tissue is not or no longer available. Compared to non-bioactive small fragment circulating tumor DNA (ctDNA), an effective identification and consecutive detection of the surrogate biomarker of viable and necrotic CTCs and CTECs during therapy may considerably promote optimization of treatment strategies, which assists in tailoring interventions to individual patients’ clinical necessities [12,13], such as appropriate selection of treatment regimen, rapid assessment of therapeutic effects and monitoring emerging resistance as well as disease progression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
